Novo Nordisk Beats Q1 Estimates Despite U.S. Pricing Pain

Pricing headwinds and a landmark 340B reversal dominate Q1 figures, but the oral Wegovy’s breakout debut points to a structural expansion of the GLP-1 market.

Key Takeaways

• Adjusted Q1 net sales fell 4% at constant exchange rates, yet oral Wegovy generated DKK 2.26 billion in its debut quarter, surpassing initial benchmarks and approaching 1.3 million total portfolio prescriptions.
• A USD 4.2 billion one-time reversal of a 340B Drug Pricing Program provision inflated reported figures; adjusted operating profit declined 6% at CER, reflecting persistent U.S. gross-to-net pricing pressure.
• Novo Nordisk raised its full-year 2026 adjusted outlook to a decline of 4–12% at CER, an improvement on prior guidance, signalling management confidence in volume momentum even as pricing normalises.

A Quarter of Two Narratives

Novo Nordisk’s first-quarter 2026 results present a challenge of interpretation that will be familiar to anyone who has followed this company closely over the past two years. The headline figures are striking: net sales of DKK 96,823 million, up 32% at constant exchange rates, operating profit surging 65% in the same measure. Yet embedded within those numbers is a USD 4.2 billion non-recurring benefit from the reversal of a provision tied to the United States’ 340B Drug Pricing Program, a dispute resolution that inflates the reported picture considerably. Strip that out, and adjusted net sales fell 4% at constant exchange rates to DKK 70,063 million, with adjusted operating profit down 6% to DKK 32,858 million.

Neither narrative, taken in isolation, captures the full picture. The company is simultaneously managing a genuine margin compression in its largest market and generating remarkable commercial momentum from a product launch that has exceeded almost every early expectation. The quarter, in that sense, is a precise reflection of where Novo Nordisk stands: a business of exceptional scientific and commercial strength navigating a pricing environment that has structurally changed.

The Pill That Changes the Conversation

The commercial debut of oral Wegovy, launched in the United States on January 5, 2026, is the defining event of the quarter and arguably the most significant milestone in the obesity treatment category since semaglutide’s injectable form reshaped clinical practice. GLP-1 therapies have, until now, been constrained by patient reluctance around self-injection and the logistical demands of subcutaneous dosing. A once-daily pill dissolves much of that friction.

The numbers from the first quarter reflect that reality forcefully. Oral Wegovy generated DKK 2,256 million in sales, supported in part by initial pipeline filling from wholesalers and pharmacies stocking up ahead of patient demand. Total prescriptions for the Wegovy portfolio approached 1.3 million across the quarter. By mid-April, weekly prescriptions for the pill alone had exceeded 200,000, and cumulative prescriptions since launch surpassed 2 million — a volume record for any GLP-1 market entry in the United States.

The significance extends beyond these immediate metrics. Pill-based delivery has the potential to expand the addressable market by reaching patients who would not otherwise initiate treatment, improving adherence rates, and simplifying the prescribing dynamic for primary care physicians less experienced with injectable therapies. If sustained, that dynamic could offset a portion of the gross-to-net pricing pressure by driving higher absolute volumes through a broader patient population.

U.S. Pricing: The Structural Challenge

Adjusted U.S. Operations sales declined 11% at constant exchange rates in the quarter. The mechanism is not obscure: lower realised prices, driven by formulary negotiations with pharmacy benefit managers, channel mix shifts toward higher-rebate segments, and the downstream effects of broader U.S. drug pricing reforms. Volume gains were real and significant; they were simply insufficient to compensate for the compression in what each unit of product ultimately yields in revenue.

This is not a Novo Nordisk-specific problem. It is a feature of the current U.S. pharmaceutical market for high-demand branded therapies, and it affects Eli Lilly’s comparable franchise in parallel ways. The competitive dimension matters here: tirzepatide, Lilly’s dual GIP/GLP-1 agonist sold as Mounjaro for diabetes and Zepbound for obesity, has established a credible rival position. Formulary competition between the two companies intensifies the pricing environment, as payers extract concessions in exchange for preferred positioning.

Management’s response has been disciplined rather than reactive. The raised full-year guidance, now projecting adjusted sales and operating profit declines of 4% to 12% at constant exchange rates against prior guidance of 5% to 13%, reflects a measured upgrade rather than a pivot. CEO Mike Doustdar framed Q1 as a strong start, with Wegovy’s performance the primary justification for that assessment.

Pipeline and Platform

Novo Nordisk’s strategic position is not solely defined by the Wegovy franchise. The quarter brought FDA approval for Awiqli, the once-weekly basal insulin icodec, adding a differentiated option in a diabetes care segment where convenience increasingly drives patient and prescriber preference. In rare diseases, etavopivat met co-primary endpoints in the Phase 3 HIBISCUS trial for sickle cell disease, extending the company’s footprint into a high-unmet-need therapeutic area.

The STEP UP trial data for Wegovy HD, the 7.2 mg injectable formulation that received FDA approval in March and launched in early April, demonstrated mean weight loss of 20.7%, reinforcing the dose-response relationship in the semaglutide platform and offering clinicians a more potent option for patients requiring greater weight reduction. International rollouts of oral Wegovy, pending local regulatory approvals, are scheduled for the second half of 2026, introducing a meaningful new volume driver outside the United States.

The initiation of the zenagamtide AMAZE Phase 3 programme in obesity extends the pipeline horizon further, though its commercial relevance lies years ahead.

Recalibration With Conviction

Full-year 2025 sales reached approximately DKK 309 billion, a figure that represented the culmination of an exceptional growth run. The current year is, by any honest measure, a period of consolidation and recalibration. Pricing normalisation in the United States, the absorption of competitive pressure, and the investment required to sustain innovation all compress the near-term financial profile.

What the first quarter demonstrates, however, is that the underlying demand for effective obesity and diabetes treatment is not in question. The oral Wegovy’s debut pace suggests that Novo Nordisk is not simply defending a franchise but actively expanding one. Volume leadership, even at lower unit economics, preserves the company’s position at the centre of what remains one of the largest commercial opportunities in modern medicine. The challenge for subsequent quarters is to demonstrate that the trajectory of that volume, combined with improving pricing visibility, can close the gap between where the business is today and the growth profile investors spent the last three years pricing in.